David Altarac
Chief Tech/Sci/R&D Officer presso ENTASIS THERAPEUTICS HOLDINGS INC.
Posizioni attive di David Altarac
Società | Posizione | Inizio | Fine |
---|---|---|---|
ENTASIS THERAPEUTICS HOLDINGS INC. | Chief Tech/Sci/R&D Officer | 04/11/2019 | - |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 04/11/2019 | - |
Storia della carriera di David Altarac
Precedenti posizioni note di David Altarac
Società | Posizione | Inizio | Fine |
---|---|---|---|
NeoStem, Inc. /Old/ | General Counsel | 01/07/2013 | 01/06/2015 |
SHIRE | Compliance Officer | 01/07/2015 | - |
General Counsel | 01/07/2015 | - | |
Caladrius Biosciences, Inc.
Caladrius Biosciences, Inc. BiotechnologyHealth Technology Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes XOWNA, CLBS12, CLBS201 and CLBS14. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. | General Counsel | 28/01/2014 | - |
Formazione di David Altarac
New York University | Graduate Degree |
New York Medical College | Doctorate Degree |
State University of New York at Binghamton | Undergraduate Degree |
NYU Wagner | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 9 |
Irlanda | 2 |
Posizioni
General Counsel | 3 |
Graduate Degree | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Settori
Health Technology | 5 |
Consumer Services | 5 |
Transportation | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 5 |
---|---|
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
NeoStem, Inc. /Old/ | Transportation |
Caladrius Biosciences, Inc.
Caladrius Biosciences, Inc. BiotechnologyHealth Technology Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes XOWNA, CLBS12, CLBS201 and CLBS14. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. | Health Technology |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Entasis Therapeutics Holdings, Inc.
Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- David Altarac
- Esperienza